Welcure Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE331C01025
NSEID:
BSEID: 524661
View on BSE

INR

0.35

0.01 (2.94%)

BSENSE

Feb 20

BSE+NSE Vol: 2.22 cr

{
  "main_header": {
    "sid": 736142,
    "name": "Welcure Drugs",
    "stock_name": "Welcure Drugs",
    "full_name": "Welcure Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/welcure-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "0.35",
    "chg": 0.01,
    "chgp": "2.94%",
    "dir": 1,
    "prev_price": "0.34",
    "mcapval": "41.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524661,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE331C01025",
    "curr_date": "Feb 20",
    "curr_time": "",
    "bse_nse_vol": "2.22 cr",
    "exc_status": "Active",
    "traded_date": "Feb 20, 2026",
    "traded_date_str": "2026 02 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/welcure-drugs-736142-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Welcure Drugs & Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/welcure-drugs-pharmaceuticals-ltd-is-rated-sell-3845619",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WelcureDrugsPha_mojoScore_3845619.png",
        "date": "2026-02-18 10:10:25",
        "description": "Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Welcure Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/welcure-drugs-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3841649",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WelcureDrugsPha_valuationdot_3841649.png",
        "date": "2026-02-16 08:03:47",
        "description": "Welcure Drugs & Pharmaceuticals Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive valuation grade. This change is underscored by its exceptionally low price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both its historical averages and peer group benchmarks, signalling a potential opportunity for value investors amid a challenging market backdrop."
      },
      {
        "title": "Welcure Drugs Gains 9.09%: Mixed Quarterly Results and Margin Pressures Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/welcure-drugs-gains-909-mixed-quarterly-results-and-margin-pressures-shape-the-week-3839794",
        "imagepath": "",
        "date": "2026-02-14 15:08:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Feb 9:</strong> Stock opens at Rs.0.34, gains 3.03% amid positive market sentiment</p>\n                    <p><strong>Feb 10:</strong> Continued upward momentum with 2.94% gain to Rs.0.35</p>\n                    <p><strong>Feb 11:</strong> Price rises further by 2.86% to Rs.0.36</p>\n                    <p><strong>Feb 12:</strong> Stock peaks at Rs.0.37 (+2.78%) despite Sensex decline</p>\n                    <p><strong>Feb 13:</strong> Mixed quarterly results trigger 2.70% fall to Rs.0.36</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.0.33</div></div>\n  ..."
      },
      {
        "title": "Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-welcure-drugs-pharmaceuticals-ltd-latest-results-good-or-bad-3838304",
        "imagepath": "",
        "date": "2026-02-13 20:07:28",
        "description": "The latest financial results for Welcure Drugs & Pharmaceuticals Ltd indicate significant operational challenges. In the quarter ending December 2025, the company reported net sales of ₹0.00 crores, marking a complete cessation of revenue generation compared to ₹65.62 crores in the previous quarter. This dramatic decline raises serious concerns regarding the company's operational viability.\n\nNet profit for the same quarter was reported at ₹1.07 crores, but this figure was largely driven by other income of ₹1.46 crores, which highlights a concerning dependency on non-operating income for profitability. The company incurred an operating loss of ₹0.03 crores, suggesting that its core pharmaceutical operations are not generating any revenue.\n\nThe operating margin fell to 0.0%, down from 17.31% in the prior quarter, reflecting a complete operational collapse. The return on equity (ROE) stands at 33.54%, which ap..."
      },
      {
        "title": "Welcure Drugs & Pharmaceuticals Ltd Reports Mixed Quarterly Results Amid Financial Trend Shift",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/welcure-drugs-pharmaceuticals-ltd-reports-mixed-quarterly-results-amid-financial-trend-shift-3837420",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WelcureDrugsPha_fintrenddot_3837420.png",
        "date": "2026-02-13 11:00:45",
        "description": "Welcure Drugs & Pharmaceuticals Ltd has reported a mixed quarterly performance for December 2025, reflecting a shift from very positive to positive financial trends. While net sales and profit after tax (PAT) have shown robust growth over the last six months, recent quarterly margins have contracted sharply, signalling operational challenges despite top-line momentum."
      },
      {
        "title": "Welcure Drugs Q3 FY26: Severe Revenue Collapse Raises Going Concern Questions",
        "link": "https://www.marketsmojo.com/news/result-analysis/welcure-drugs-q3-fy26-severe-revenue-collapse-raises-going-concern-questions-3837783",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WelcureDrugsPha_quaterlyResult_3837783.png",
        "date": "2026-02-13 09:38:06",
        "description": "Welcure Drugs & Pharmaceuticals Ltd. reported a catastrophic operational collapse in Q3 FY26, with net sales plummeting to zero from ₹65.62 crores in the previous quarter, whilst the micro-cap pharmaceutical company posted a net profit of ₹1.07 crores entirely driven by non-operating income. The stock, trading at ₹0.36 with a market capitalisation of just ₹44.49 crores, has crashed 56.52% over the past year and now trades 74.83% below its 52-week high of ₹1.43, reflecting severe investor concerns about business viability."
      },
      {
        "title": "Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-welcure-drugs-pharmaceuticals-ltd-latest-results-good-or-bad-3835786",
        "imagepath": "",
        "date": "2026-02-12 19:52:56",
        "description": "The latest financial results for Welcure Drugs & Pharmaceuticals Ltd for the second quarter of FY26 present a complex picture. The company reported a net profit of ₹8.50 crores, which reflects a significant year-on-year improvement of 362% compared to ₹1.84 crores in Q2 FY24. However, this figure represents a sequential decline of 63.52% from the previous quarter's net profit of ₹23.30 crores, raising concerns about the consistency of earnings.\n\nRevenue for the same quarter was ₹65.62 crores, marking a dramatic 78.12% decline from ₹299.91 crores in Q1 FY26. This volatility in revenue suggests that the company's income may be heavily influenced by project-based recognition rather than stable operational performance. The operating margin improved to 17.31%, up from 10.38% in the prior quarter, indicating enhanced operational efficiency when revenue is realized. Additionally, the profit after tax margin rose t..."
      },
      {
        "title": "Welcure Drugs & Pharmaceuticals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/welcure-drugs-pharmaceuticals-ltd-is-rated-sell-3825820",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WelcureDrugsPha_mojoScore_3825820.png",
        "date": "2026-02-07 10:10:19",
        "description": "Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 February 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Welcure Drugs & Pharmaceuticals Ltd Falls to 52-Week Low of Rs.0.28",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/welcure-drugs-pharmaceuticals-ltd-falls-to-52-week-low-of-rs028-3818322",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WelcureDrugsPha_priceRelatedfactors_3818322.png",
        "date": "2026-02-03 10:48:42",
        "description": "Welcure Drugs & Pharmaceuticals Ltd has touched a new 52-week and all-time low of Rs.0.28, marking a significant decline in its stock price amid a challenging market environment. This latest low reflects a steep downturn over the past year, with the stock underperforming its sector and benchmark indices."
      }
    ],
    "total": 283,
    "sid": "736142",
    "stock_news_url": "https://www.marketsmojo.com/news/welcure-drugs-pharmaceuticals-736142"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Feb-2026",
      "details": "Newspaper Clipping of Unaudited Financials for 3rd Quarter ended December 21 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The 3Rd Quarter Ended On 31St December 2025.",
      "datetime": "12-Feb-2026",
      "details": "Unaudited Financials Results for the 3rd Quarter ended on 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Thursday 12Th February 2026",
      "datetime": "12-Feb-2026",
      "details": "Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Thursday 12th February 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Welcure Drugs & Pharmaceuticals Ltd has announced <strong>1:10</strong> stock split, ex-date: 16 Oct 25",
          "dt": "2025-10-16",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Welcure Drugs & Pharmaceuticals Ltd has announced <strong>1:10</strong> bonus issue, ex-date: 16 Oct 25",
          "dt": "2025-10-16",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Welcure Drugs & Pharmaceuticals Ltd is Rated Sell

2026-02-18 10:10:25

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Welcure Drugs & Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness

2026-02-16 08:03:47

Welcure Drugs & Pharmaceuticals Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive valuation grade. This change is underscored by its exceptionally low price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both its historical averages and peer group benchmarks, signalling a potential opportunity for value investors amid a challenging market backdrop.

Read full news article

Welcure Drugs Gains 9.09%: Mixed Quarterly Results and Margin Pressures Shape the Week

2026-02-14 15:08:37

Key Events This Week

Feb 9: Stock opens at Rs.0.34, gains 3.03% amid positive market sentiment

Feb 10: Continued upward momentum with 2.94% gain to Rs.0.35

Feb 11: Price rises further by 2.86% to Rs.0.36

Feb 12: Stock peaks at Rs.0.37 (+2.78%) despite Sensex decline

Feb 13: Mixed quarterly results trigger 2.70% fall to Rs.0.36

Week Open

Rs.0.33

...

Read full news article

Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?

2026-02-13 20:07:28

The latest financial results for Welcure Drugs & Pharmaceuticals Ltd indicate significant operational challenges. In the quarter ending December 2025, the company reported net sales of ₹0.00 crores, marking a complete cessation of revenue generation compared to ₹65.62 crores in the previous quarter. This dramatic decline raises serious concerns regarding the company's operational viability. Net profit for the same quarter was reported at ₹1.07 crores, but this figure was largely driven by other income of ₹1.46 crores, which highlights a concerning dependency on non-operating income for profitability. The company incurred an operating loss of ₹0.03 crores, suggesting that its core pharmaceutical operations are not generating any revenue. The operating margin fell to 0.0%, down from 17.31% in the prior quarter, reflecting a complete operational collapse. The return on equity (ROE) stands at 33.54%, which ap...

Read full news article

Welcure Drugs & Pharmaceuticals Ltd Reports Mixed Quarterly Results Amid Financial Trend Shift

2026-02-13 11:00:45

Welcure Drugs & Pharmaceuticals Ltd has reported a mixed quarterly performance for December 2025, reflecting a shift from very positive to positive financial trends. While net sales and profit after tax (PAT) have shown robust growth over the last six months, recent quarterly margins have contracted sharply, signalling operational challenges despite top-line momentum.

Read full news article

Welcure Drugs Q3 FY26: Severe Revenue Collapse Raises Going Concern Questions

2026-02-13 09:38:06

Welcure Drugs & Pharmaceuticals Ltd. reported a catastrophic operational collapse in Q3 FY26, with net sales plummeting to zero from ₹65.62 crores in the previous quarter, whilst the micro-cap pharmaceutical company posted a net profit of ₹1.07 crores entirely driven by non-operating income. The stock, trading at ₹0.36 with a market capitalisation of just ₹44.49 crores, has crashed 56.52% over the past year and now trades 74.83% below its 52-week high of ₹1.43, reflecting severe investor concerns about business viability.

Read full news article

Are Welcure Drugs & Pharmaceuticals Ltd latest results good or bad?

2026-02-12 19:52:56

The latest financial results for Welcure Drugs & Pharmaceuticals Ltd for the second quarter of FY26 present a complex picture. The company reported a net profit of ₹8.50 crores, which reflects a significant year-on-year improvement of 362% compared to ₹1.84 crores in Q2 FY24. However, this figure represents a sequential decline of 63.52% from the previous quarter's net profit of ₹23.30 crores, raising concerns about the consistency of earnings. Revenue for the same quarter was ₹65.62 crores, marking a dramatic 78.12% decline from ₹299.91 crores in Q1 FY26. This volatility in revenue suggests that the company's income may be heavily influenced by project-based recognition rather than stable operational performance. The operating margin improved to 17.31%, up from 10.38% in the prior quarter, indicating enhanced operational efficiency when revenue is realized. Additionally, the profit after tax margin rose t...

Read full news article

Welcure Drugs & Pharmaceuticals Ltd is Rated Sell

2026-02-07 10:10:19

Welcure Drugs & Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 14 Nov 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 February 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Welcure Drugs & Pharmaceuticals Ltd Falls to 52-Week Low of Rs.0.28

2026-02-03 10:48:42

Welcure Drugs & Pharmaceuticals Ltd has touched a new 52-week and all-time low of Rs.0.28, marking a significant decline in its stock price amid a challenging market environment. This latest low reflects a steep downturn over the past year, with the stock underperforming its sector and benchmark indices.